Phase II trial of neoadjuvant chemotherapy with XELOX plus Bevacizumab for locally advanced rectal cancer
Phase 2
- Conditions
- ocally advanced rectal cancer
- Registration Number
- JPRN-UMIN000003507
- Lead Sponsor
- agoya Surgical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Multiple malignacies to be treated 2. Uncontrollable peptic ulcer disease 3. Serious complications 4. Previous history of severe drug-induced allergy 5. Severe neuropathy 6. With interstitial lung disease or pulmonary fibrosis 7. Pregnant 8. Prior chemotherapy with bevacizumab, oxaliplatin or capecitabin 9. Disqualified by attending docor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment compliance
- Secondary Outcome Measures
Name Time Method Overall survival, disease free survival, local recurrence rate, response rate